Marksans Pharma's Latest Updates

Recent Regulatory Approvals and Authorizations Marksans' wholly-owned UK subsidiary, Relonchem Limited, has received multiple Marketing Authorizations from the UK's MHRA. Recent UK MHRA approvals include Metformin Hydrochloride Prolonged release tablets (500mg, 750mg, and 1000mg), Metformin Oral Solution, Oxybutynin Hydrochloride oral solution, and other products like Gabapentin oral solution and Sennosides tablets. The company's US subsidiary, Marksans Pharma Inc. or Time-Cap Laboratories, Inc., received final US FDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC), a generic equivalent to Prilosec. Manufacturing and Inspection Updates Marksans Pharma's US subsidiary, Time-Cap Laboratories, Inc., successfully received an Establishment Inspection Report (EIR) from the US FDA following a cGMP inspection at its New York facility in April 2025, with only one inspectional observation and no data integrity issues. The company is also addressing five inspectional observations noted in a Form 483 received from the US FDA after a cGMP inspection at its Verna, Goa facility in April 2024. Corporate and Financial Announcements The company declared its financial results for the quarter ended June 30, 2025 (Q1 FY26), reporting a consolidated revenue of approximately ₹620 crore, which was up 5% year-on-year. Marksans Pharma announced the grant of 4,00,000 options to eligible employees under the 'Marksans Employees Stock Option Scheme 2024'. The company has also announced the closure of its trading window for the quarter and half-year ended September 2025.